Acute Respiratory Distress Syndrome Disease Pipeline Drugs Assessment: Clinical Trials Analysis, Player Profiles, Collaborations, Key Targets, Geographic Focus, and Data Publications, 2019 - 2030

Purchase Option

$ 4400
$ 4000
$ 6000

Acute Respiratory Distress Syndrome is an acute lung dysfunction, which occurs as a result of injury or illness. It is known as adult respiratory distress syndrome, it may also affect children. In this condition, small air sacs (alveoli) in the lungs are accumulated with fluid which makes difficulty in passing oxygen into blood stream. Symptoms of acute respiratory distress syndrome include difficulty in breathing, rapid breathing, and hyper ventilation. ARDS can be developed into deep infection which causes pneumonia, trauma.

ARDS can be diagnosed by blood tests, chest x-rays and others. Treatment for the ARDS are mechanical ventilation, supplemental oxygen, fluid management and a technique called positive end expiratory pressure (PEEP) to help push the fluid out of air sacs, extracorporeal membrane oxygenation, and human mesenchymal stem cells.

 Key Developments: 

  • In January 2016, Chiesi Farmaceutici S.p.A initiated phase II clinical trials of its CHF 5633 in neonatal respiratory distress syndrome.
  • In August 2017, BioMarck Pharmaceuticals initiated Phase-II clinical trials in Adult respiratory distress syndrome in USA (Inhalation)

Acute Respiratory Distress Syndrome Disease Pipeline Drugs Assessment Dynamics

Acute Respiratory Distress Syndrome Disease Pipeline Drugs Assessment report studies the various therapeutics under clinical development for Acute Respiratory Distress Syndrome treatment along with targets for various drug candidate. The report provides plethora of information pertaining to trail phases, companies involved in the Acute Respiratory Distress Syndrome disease pipeline drugs development. This report studies the dynamics of the Acute Respiratory Distress Syndrome Disease Pipeline Drugs i.e. drivers, challenges and opportunities which are significantly impacting the product development. The report provides various information pertaining the clinical trials such as designation, grants, patents, and technology among others. Moreover, the report on Acute Respiratory Distress Syndrome disease pipeline drugs assessment comprehensively presents the geographic location, trial status information along with key players involved in the therapeutics development.

Acute Respiratory Distress Syndrome Disease Pipeline Drugs Assessment Segmentation

By Drugs
  • Interferon Beta-1a
  • Imatinib
  • Sivelestat
  • L-Citrulline
  • Poractantalfa
  • Ganciclovir
  • Others
By Route of Administration
  • Oral
  • Parenteral
By Trial Phase
  • Preclinical Trials
  • Phase 1
  • Phase 2
  • Phase 3
  • Phase 4
By Company

 

  • AltorBioScience
  • Genentech, Inc.
  • Faron Pharmaceuticals Ltd.
  • AltorBioScience
  • Suntory Pharmaceutical
  • Eli Lilly and Company
  • Asklepion Pharmaceuticals, LLC
  • BioMarck Pharmaceuticals, Ltd.
  • Others

Frequently Asked Questions

2021 is the base year and 2028 is the forecast year.

The report covers the five regions and 15+ countries market data: North America (United States, Canada), Europe (Germany, France, Italy, Spain, and United Kingdom (UK), Asia Pacific (China, India, Japan, Australia & New Zealand), Latin America (Brazil, Mexico, Argentina) and Middle East and Africa (Saudi Arabia, United Arab Emirates, South Africa).

In our report, we provide 12-15 market players’ information into the report. However, based on the client’s request we will provide additional country and regional market players information as well.

Key Features of the Reports

  • The report provides granular level information about the market size, regional market share, historic market (2019-2023), and forecast (2024-2030)
  • The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments, and start-up details that are actively working in the market
  • The report provides a plethora of information about market entry strategies, regulatory framework, and reimbursement scenario

1. Executive Summary

 2. Global Acute Respiratory Distress Syndrome Disease Pipeline Drugs Assessment Market Introduction

 2.1. Global Acute Respiratory Distress Syndrome Disease Pipeline Drugs Assessment Market Taxonomy

2.2. Global Acute Respiratory Distress Syndrome Disease Pipeline Drugs Assessment Market Definitions

2.2.1. Drugs

2.2.2. Route of Administration

2.2.3. Trial Phase

 3. Global Acute Respiratory Distress Syndrome Disease Pipeline Drugs Assessment Market Dynamics

 3.1. Drivers

3.2. Restraints

3.3. Opportunities/Unmet Needs of the Market

3.4. Trends

3.5. Global Acute Respiratory Distress Syndrome Disease Pipeline Drugs Assessment Market Dynamic Factors - Impact Analysis

3.6. Global Acute Respiratory Distress Syndrome Disease Pipeline Drugs Assessment Market Competition Landscape

3.7. Epidemiology

4. Global Acute Respiratory Distress Syndrome Disease Pipeline Drugs Assessment Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030

4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)

4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)

4.3. Market opportunity analysis

5. Global Acute Respiratory Distress Syndrome Disease Pipeline Drugs Assessment Market, By Drugs, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)

5.1. Interferon Beta-1a

5.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)

5.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

5.1.3. Market Opportunity Analysis

5.2. Imatinib

5.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)

5.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

5.2.3. Market Opportunity Analysis

5.3. Sivelestat

5.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)

5.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

5.3.3. Market Opportunity Analysis

5.4. L-Citrulline

5.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)

5.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

5.4.3. Market Opportunity Analysis

5.5. Poractantalfa

5.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)

5.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

5.5.3. Market Opportunity Analysis

5.6. Ganciclovir

5.6.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)

5.6.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

5.6.3. Market Opportunity Analysis

5.7. Others

5.7.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)

5.7.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

5.7.3. Market Opportunity Analysis

6. Global Acute Respiratory Distress Syndrome Disease Pipeline Drugs Assessment Market Forecast, By Route of Administration,2019 - 2023 and Forecast, 2017 - 2030

6.1.  Oral

6.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)

6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

6.1.3. Market Opportunity Analysis

6.2. Parenteral

6.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)

6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

6.2.3. Market Opportunity Analysis

7. Global Acute Respiratory Distress Syndrome Disease Pipeline Drugs Assessment Market Forecast, By Trial Phase, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)

7.1. Preclinical Trials

7.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)

7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

7.1.3. Market Opportunity Analysis

7.2. Phase 1

7.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)

7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

7.2.3. Market Opportunity Analysis

7.3. Phase 2

7.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)

7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

7.3.3. Market Opportunity Analysis

7.4. Phase 3

7.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)

7.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

7.4.3. Market Opportunity Analysis

7.5. Phase 4

7.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)

7.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

7.5.3. Market Opportunity Analysis

8. Global Acute Respiratory Distress Syndrome Disease Pipeline Drugs Assessment Market Forecast, By Region, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)

8.1. North America

8.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)

8.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

8.1.3. Market Opportunity Analysis

8.2. Europe

8.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)

8.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

8.2.3. Market Opportunity Analysis

8.3. Asia-Pacific

8.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)

8.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

8.3.3. Market Opportunity Analysis

8.4. Latin America

8.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)

8.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

8.4.3. Market Opportunity Analysis

8.5. Middle East and Africa

8.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)

8.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

8.5.3. Market Opportunity Analysis

8.6. Global Acute Respiratory Distress Syndrome Disease Pipeline Drugs Assessment Market - Opportunity Analysis Index, By Drugs, By Route of Administration, By Trial Phase and Region, 2024 - 2030

9. North America Acute Respiratory Distress Syndrome Disease Pipeline Drugs Assessment Market Analysis,2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)

9.1. Drugs Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn),Y-o-Y Growth (%), and Market Share (%)

9.1.1. Interferon Beta-1a

9.1.2. Imatinib

9.1.3. Sivelestat

9.1.4. L-Citrulline

9.1.5. Poractantalfa

9.1.6. Ganciclovir

9.1.7. Others

9.2. Route of Administration Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

9.2.1. Oral

9.2.2. Parenteral

9.3. Trial Phase Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

9.3.1. Preclinical Trials

9.3.2. Phase 1

9.3.3. Phase 2

9.3.4. Phase 3

9.3.5. Phase 4

9.4. Country Analysis 2016 and Forecast 2024 - 2030 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)

9.4.1. U.S.

9.4.2. Canada

9.5. North America Acute Respiratory Distress Syndrome Disease Pipeline Drugs Assessment Market - Opportunity Analysis Index, By Drugs, By Route of Administration, By Trial Phase and Region, 2024 - 2030

9.6. North America Acute Respiratory Distress Syndrome Disease Pipeline Drugs Assessment Market Dynamics Trends

10. Europe Acute Respiratory Distress Syndrome Disease Pipeline Drugs Assessment Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)

10.1. Drugs Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn),Y-o-Y Growth (%), and Market Share (%)

10.1.1. Interferon Beta-1a

10.1.2. Imatinib

10.1.3. Sivelestat

10.1.4. L-Citrulline

10.1.5. Poractantalfa

10.1.6. Ganciclovir

10.1.7. Others

10.2. Route of Administration Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

10.2.1. Oral

10.2.2. Parenteral

10.3. Trial Phase Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

10.3.1. Preclinical Trials

10.3.2. Phase 1

10.3.3. Phase 2

10.3.4. Phase 3

10.3.5. Phase 4

10.4. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)

10.4.1. Germany

10.4.2. UK

10.4.3. France

10.4.4. Spain

10.4.5. Italy

10.4.6. Russia

10.4.7. Poland

10.4.8. Rest of Europe

10.5. Europe Acute Respiratory Distress Syndrome Disease Pipeline Drugs Assessment Market - Opportunity Analysis Index, By Drugs, By Route of Administration, By Trial Phase and Region, 2024 - 2030

10.6. Europe Acute Respiratory Distress Syndrome Disease Pipeline Drugs Assessment Market Dynamics Trends

11. Asia-Pacific Acute Respiratory Distress Syndrome Disease Pipeline Drugs Assessment Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)

11.1. Drugs Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn),Y-o-Y Growth (%), and Market Share (%)

11.1.1. Interferon Beta-1a

11.1.2. Imatinib

11.1.3. Sivelestat

11.1.4. L-Citrulline

11.1.5. Poractantalfa

11.1.6. Ganciclovir

11.1.7. Others

11.2. Route of Administration Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

11.2.1. Oral

11.2.2. Parenteral

11.3. Trial Phase Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

11.3.1. Preclinical Trials

11.3.2. Phase 1

11.3.3. Phase 2

11.3.4. Phase 3

11.3.5. Phase 4

11.4. Country Analysis2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)       

11.4.1. Japan

11.4.2. China

11.4.3. India

11.4.4. ASEAN

11.4.5. Australia & New Zealand

11.4.6. Rest of Asia-Pacific

11.5. Asia-Pacific Acute Respiratory Distress Syndrome Disease Pipeline Drugs Assessment Market - Opportunity Analysis Index, By Drugs, By Route of Administration, By Trial Phase and Region, 2024 - 2030

11.6. Asia-PacificAcute Respiratory Distress Syndrome Disease Pipeline Drugs Assessment Market Dynamics Trends

12. Latin America Acute Respiratory Distress Syndrome Disease Pipeline Drugs Assessment Market Analysis, 2012 - 2012 - 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)

12.1. Drugs Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn),Y-o-Y Growth (%), and Market Share (%)

12.1.1. Interferon Beta-1a

12.1.2. Imatinib

12.1.3. Sivelestat

12.1.4. L-Citrulline

12.1.5. Poractantalfa

12.1.6. Ganciclovir

12.1.7. Others

12.2. Route of Administration Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

12.2.1. Oral

12.2.2. Parenteral

12.3. Trial Phase Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

12.3.1. Preclinical Trials

12.3.2. Phase 1

12.3.3. Phase 2

12.3.4. Phase 3

12.3.5. Phase 4

12.4. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)

12.4.1. Brazil

12.4.2. Mexico

12.4.3. Argentina

12.4.4. Venezuela

12.4.5. Rest of Latin America

12.5. Latin America Acute Respiratory Distress Syndrome Disease Pipeline Drugs Assessment Market - Opportunity Analysis Index, By Drugs, By Route of Administration, By Trial Phase and Region, 2024 - 2030

12.6. Latin America Acute Respiratory Distress Syndrome Disease Pipeline Drugs Assessment Market Dynamics Trends

13. Middle East and Africa Acute Respiratory Distress Syndrome Disease Pipeline Drugs Assessment Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)

13.1. Drugs Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn),Y-o-Y Growth (%), and Market Share (%)

13.1.1. Interferon Beta-1a

13.1.2. Imatinib

13.1.3. Sivelestat

13.1.4. L-Citrulline

13.1.5. Poractantalfa

13.1.6. Ganciclovir

13.1.7. Others

13.2. Route of Administration Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

13.2.1. Oral

13.2.2. Parenteral

13.3. Trial Phase Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

13.3.1. Preclinical Trials

13.3.2. Phase 1

13.3.3. Phase 2

13.3.4. Phase 3

13.3.5. Phase 4

13.4. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)

13.4.1. Gulf Cooperation Council (GCC) Countries

13.4.2. Israel

13.4.3. South Africa

13.4.4. Rest of MEA

13.5. MEA Acute Respiratory Distress Syndrome Disease Pipeline Drugs Assessment Market - Opportunity Analysis Index, By Drugs, By Route of Administration, By Trial Phase and Region, 2024 - 2030

13.6. MEA Acute Respiratory Distress Syndrome Disease Pipeline Drugs Assessment Market Dynamics Trends

14. Competition Landscape

14.1. Strategic Dashboard of Top Market Players

14.2. Company Profiles (Introduction, Financial Analysis, Drug Class& Service Offerings, Key Developments, Strategies, and SWOT Analysis)

14.2.1. AltorBioScience

14.2.2. Genentech, Inc.

14.2.3. Faron Pharmaceuticals Ltd.

14.2.4. AltorBioScience

14.2.5. Suntory Pharmaceutical

14.2.6. Eli Lilly and Company

14.2.7. Asklepion Pharmaceuticals, LLC

14.2.8. BioMarck Pharmaceuticals, Ltd.

14.2.9. Others

15. Research Methodology

16. Key Assumptions and Acronyms

  • AltorBioScience
  • Genentech, Inc.
  • Faron Pharmaceuticals Ltd.
  • AltorBioScience
  • Suntory Pharmaceutical
  • Eli Lilly and Company
  • Asklepion Pharmaceuticals, LLC
  • BioMarck Pharmaceuticals, Ltd.

Adjacent Markets